NEKTAR THERAPEUTICS (NKTR): Results of Operations and Financial Condition
NEKTAR THERAPEUTICS (NKTR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Nektar Therapeutics Announces Second Quarter 2026 Financial Results SAN FRANCISCO, Aug 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today reported financial r
How this was made
The 30-second read
Why it matters
Traders can update positioning based on (1) the disclosed cash and runway, (2) the start of the first two registrational Phase 3 ZENITH AD trials, and (3) the updated cost structure from higher R&D spend.
Market read
The 8-K provides fresh, tradable disclosures: a large cash balance jump, a stated runway into Q3 2028, and initiation of registrational Phase 3 trials.
What to watch
The article highlights increased R&D tied to Phase 3 and manufacturing, but provides no new Phase 3 efficacy or safety data, which may temper the immediate reaction.
Nektar Therapeutics Announces Second Quarter 2026 Financial Results
Nektar entered Phase 3 activity for rezpegaldesleukin and reported cash and investments in marketable securities of $1,023.4 million, but second-quarter revenue declined to $10.1 million and operating costs and expenses increased to $52.5 million as Phase 3 and manufacturing activities raised R&D expense.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| RevenueGAAP | $10.1 million | – | – |
| Revenue, first halfGAAP | $21.0 million | – | – |
| Total operating costs and expensesGAAP | $52.5 million | – | – |
| Total operating costs and expenses, first halfGAAP | $102.4 million | – | – |
| Research and development expenseGAAP | $39.1 million | – | – |
| Research and development expense, first halfGAAP | $74.8 million | – | – |
| General and administrative expenseGAAP | $12.8 million | – | – |
| General and administrative expense, first halfGAAP | $26.2 million | – | – |
| Non-cash loss from equity method investment in Gannet BioChemGAAP | $0.3 million | – | – |
| Non-cash loss from equity method investment in Gannet BioChem, first halfGAAP | $2.1 million | – | – |
| Net lossGAAP | $40.6 million | – | – |
| Basic and diluted net loss per shareGAAP | $1.23 basic and diluted net loss per share | – | – |
| Net loss, first halfGAAP | $85.5 million | – | – |
| Basic and diluted net loss per share, first halfGAAP | $2.96 basic and diluted net loss per share | – | – |
| Cash and investments in marketable securitiesother | $1,023.4 million | – | – |
| Cash and cash equivalentsother | $39,267 | – | – |
| Short-term investmentsother | 645,074 | – | – |
| Other current assetsother | 55,061 | – | – |
| Total current assetsother | 739,402 | – | – |
| Long-term investmentsother | 339,061 | – | – |
| Other assetsother | 16,666 | – | – |
| Total assetsother | $1,095,129 | – | – |
Through the third quarter of 2028 outlook
- NoteCash runway that extends into the third quarter of 2028
- NotePlan to start a single registrational Phase 3 study in alopecia areata in early 2027
- NoteFirst BLA submission for rezpegaldesleukin in 2029
- NoteInitial Phase 3 data readouts expected in mid-2028
What drove it
- R&D expense increased primarily due to the commencement of activities to support the Phase 3 ZENITH AD program in atopic dermatitis and manufacturing activities associated with rezpegaldesleukin.
- G&A expense decreased primarily due to a decrease in legal expenses.
- Nektar initiated the first two global registrational trials in the Phase 3 ZENITH AD program in July 2026.
- The Phase 3 ZENITH AD program includes three randomized, double-blind, placebo-controlled trials in moderate-to-severe atopic dermatitis.
- Nektar announced positive 52-week topline results from the Phase 2b REZOLVE-AA study in April 2026.
Concerns
- Second-quarter revenue was $10.1 million, compared with $11.2 million in the second quarter of 2025.
- Total operating costs and expenses were $52.5 million, compared with $47.4 million in the second quarter of 2025.
- R&D expense was $39.1 million, compared with $29.9 million in the second quarter of 2025, reflecting Phase 3 and manufacturing activities.
- Rezpegaldesleukin and the company’s other drug candidates are investigational agents, and continued research and development is subject to risks including negative safety and efficacy findings in future clinical studies.
- Clinical-trial initiation, completion, and data availability may be delayed by regulatory delays, enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, trial design, clinical outcomes, and competitive factors.
What to watch
- Initiation of the planned single registrational Phase 3 study in alopecia areata in early 2027.
- Initial Phase 3 data readouts expected in mid-2028.
- The stated cash runway into the third quarter of 2028.
- The planned first BLA submission for rezpegaldesleukin in 2029.
- Phase 2b REZOLVE-AD and REZOLVE-AA presentations at the 2026 European Academy of Dermatology and Venereology Congress on Thursday, October 1.
Balance sheet and cash flow
- Cash and investments in marketable securities on June 30, 2026, were $1,023.4 million as compared to $245.8 million on December 31, 2025.
- Cash and cash equivalents were $39,267 at June 30, 2026, compared with $15,116 at December 31, 2025. (In thousands)
- Short-term investments were 645,074 at June 30, 2026, compared with 230,636 at December 31, 2025. (In thousands)
- Long-term investments were 339,061 at June 30, 2026, compared with - at December 31, 2025. (In thousands)
- In April 2026, Nektar completed an underwritten public offering of its common stock resulting in $373.8 million of gross proceeds.
Analysis
Nektar reported second-quarter revenue of $10.1 million, compared with $11.2 million in the second quarter of 2025. First-half revenue was $21.0 million, compared with $21.6 million in the first half of 2025. The company remained loss-making, reporting a second-quarter net loss of $40.6 million and $1.23 basic and diluted net loss per share, compared with a net loss of $41.6 million and $2.95 basic and diluted loss per share in the prior-year quarter.
Expense mix shifted toward clinical development. Total operating costs and expenses were $52.5 million, compared with $47.4 million in the second quarter of 2025. R&D expense increased to $39.1 million from $29.9 million, driven primarily by commencement of Phase 3 ZENITH AD activities and rezpegaldesleukin manufacturing. This was partly offset by G&A expense of $12.8 million, compared with $17.1 million, primarily due to lower legal expenses.
The central business development was the July initiation of the first two global registrational Phase 3 ZENITH AD trials in moderate-to-severe atopic dermatitis. The program is planned to include three randomized, double-blind, placebo-controlled trials. Nektar also cited positive 52-week topline results from the Phase 2b REZOLVE-AA study and plans to start a single registrational Phase 3 study in alopecia areata in early 2027.
Liquidity strengthened following the April underwritten public offering, which generated $373.8 million of gross proceeds. Cash and investments in marketable securities were $1,023.4 million at June 30, 2026, compared with $245.8 million at December 31, 2025. Management stated that this cash runway extends into the third quarter of 2028, beyond initial Phase 3 data readouts expected in mid-2028.
The reported outlook is clinical rather than revenue or margin guidance. Management identified an expected first BLA submission for rezpegaldesleukin in 2029. Execution on the ZENITH AD studies, the planned alopecia areata registrational study, manufacturing activities, and preservation of the stated cash runway are the principal reported items to follow.
Management, verbatim
This year continues to be a transformative year for Nektar as we advance our lead program, rezpegaldesleukin, into Phase 3 clinical trials.
Howard W. Robin, President and Chief Executive Officer of Nektar
We initiated the first Phase 3 ZENITH AD trials in atopic dermatitis in July, and we plan to start a single registrational Phase 3 study in alopecia areata in early 2027.
Howard W. Robin, President and Chief Executive Officer of Nektar
Importantly, our financial position is strong with over one billion dollars in cash and investments at the end of the quarter, and a cash runway that extends into the third quarter of 2028, past the initial Phase 3 data readouts expected in mid-2028.
Howard W. Robin, President and Chief Executive Officer of Nektar
Not in the filing
stated, not guessed- Gross profit and gross margin
- Operating income or loss
- Non-GAAP revenue, earnings, EPS, or profitability metrics
- Prior-quarter comparisons for reported income-statement metrics
- Reported year-over-year or quarter-over-quarter percentage changes for reported metrics
- Segment revenue and segment-level comparisons
- Operating cash flow
- Free cash flow
- Debt balance
- Full balance-sheet liabilities and stockholders’ equity data, as the provided filing text is truncated
- Dividends and share repurchases
- Financial revenue, gross-margin, operating-expense, or tax-rate guidance
- Previous-release outlook for comparison with actual results
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is an SEC Form 8-K with Exhibit 99.1 covering Nektar’s Q2 2026 financial results and business updates for rezpegaldesleukin (NKTR-358).
Ticker impact
Nektar reported Q2 2026 results and said it initiated Phase 3 ZENITH AD-1 and AD-2 trials, with cash and runway into Q3 2028.
Near-term sentiment likely positive on the Phase 3 initiation and cash runway disclosure, with volatility around future Phase 3 readouts.
The 8-K includes primary financial datapoints (cash jump, R&D spend) and a specific clinical action (first two registrational Phase 3 trials started in July). However, it does not provide new efficacy results or guidance beyond the stated program timeline.
Market effects
Reinforces investor appetite for clinical-stage immunology assets with credible Phase 3 funding runway and registrational trial starts.
Limited; primarily US biotech sentiment with potential spillover to other dermatology/immunology developers.
Low; the disclosed catalysts are company-specific and tied to US-listed clinical development timelines.
Counterpoint
Despite the cash increase, the company is still reporting large operating losses and rising R&D, so the stock may remain sensitive to Phase 3 execution risk.
Key entities
- companyNektar Therapeutics
Clinical-stage biotech developing rezpegaldesleukin for autoimmune and chronic inflammatory diseases; subject of the 8-K.
- programrezpegaldesleukin (NKTR-358)
Lead candidate advancing into Phase 3 ZENITH AD trials, with a stated path to BLA submission in 2029.
- clinical_trialsZENITH AD Phase 3 program
Registrational trials in atopic dermatitis; first two global registrational trials (AD-1 and AD-2) initiated in July 2026.
